PMID- 31321819
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201029
IS  - 1360-0443 (Electronic)
IS  - 0965-2140 (Linking)
VI  - 114
IP  - 11
DP  - 2019 Nov
TI  - Psychostimulant use and the brain.
PG  - 2065-2077
LID - 10.1111/add.14708 [doi]
AB  - Psychostimulant users are typically young adults. We have conducted a narrative 
      review of neuropsychiatric harms associated with the psychostimulants 
      methamphetamine/amphetamine, cocaine and 3,4-methylenedioxymethamphetamine 
      (MDMA), focusing on epidemiological factors, common clinical presentations, 
      underlying causal mechanisms and treatment options. The major neuropsychiatric 
      harms of psychostimulant use are stroke, neurocognitive impairment, Parkinson's 
      disease, seizures and psychotic illness. These arise through a combination of 
      acute monoamine release, longer-term neurotransmitter effects and indirect 
      effects. These effects are moderated by factors in the individual and in the 
      pattern of substance use. Neuropsychiatric harms associated with psychostimulant 
      use can thus lead to severe long-term impairment.
CI  - (c) 2019 Society for the Study of Addiction.
FAU - Lappin, Julia M
AU  - Lappin JM
AUID- ORCID: 0000-0001-5946-2144
AD  - National Drug and Alcohol Research Centre (NDARC), University of New South Wales, 
      Sydney, Australia.
AD  - School of Psychiatry, University of New South Wales, Sydney, Australia.
FAU - Sara, Grant E
AU  - Sara GE
AD  - InforMH, NSW Ministry of Health, North Ryde, NSW, Australia.
AD  - Northern Clinical School, Sydney Medical School, The University of Sydney, 
      Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190719
PL  - England
TA  - Addiction
JT  - Addiction (Abingdon, England)
JID - 9304118
RN  - 0 (Central Nervous System Stimulants)
RN  - 44RAL3456C (Methamphetamine)
RN  - CK833KGX7E (Amphetamine)
RN  - I5Y540LHVR (Cocaine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Amphetamine/adverse effects
MH  - Amphetamine-Related Disorders/metabolism/physiopathology
MH  - Brain/metabolism/physiopathology
MH  - Central Nervous System Stimulants/*adverse effects
MH  - Cocaine/adverse effects
MH  - Cocaine-Related Disorders/metabolism/physiopathology
MH  - Cognitive Dysfunction/*chemically induced/metabolism/physiopathology
MH  - Humans
MH  - Methamphetamine/adverse effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
MH  - Parkinson Disease, Secondary/*chemically induced/metabolism/physiopathology
MH  - Psychoses, Substance-Induced/*etiology/metabolism/physiopathology
MH  - Seizures/*chemically induced/metabolism/physiopathology
MH  - Stroke/*chemically induced/metabolism/physiopathology
OTO - NOTNLM
OT  - Amphetamine
OT  - MDMA
OT  - Parkinson's disease
OT  - cocaine
OT  - methamphetamine
OT  - neurocognition
OT  - psychosis
OT  - psychostimulants
OT  - seizure
OT  - stroke
EDAT- 2019/07/20 06:00
MHDA- 2020/10/30 06:00
CRDT- 2019/07/20 06:00
PHST- 2019/02/17 00:00 [received]
PHST- 2019/04/01 00:00 [revised]
PHST- 2019/06/03 00:00 [accepted]
PHST- 2019/07/20 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
PHST- 2019/07/20 06:00 [entrez]
AID - 10.1111/add.14708 [doi]
PST - ppublish
SO  - Addiction. 2019 Nov;114(11):2065-2077. doi: 10.1111/add.14708. Epub 2019 Jul 19.